Fulcrum Therapeutics, Inc. (FULC) Stock Forecast
FULC analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 2.80 / 5 from 5 analysts
- Price target
- $3.67 average of analyst targets
- Upside to target
- +0.5% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.10
- 52-week range
- $3.14 – $14.60
FULC analyst ratings
5 analystsNumber of analysts at each rating.
FULC price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
FULC earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.11 | −$0.13 | −$0.08 | −$0.31 | +65.6% | 2 |
| Current fiscal year (2026) | −$0.66 | −$0.81 | −$0.51 | −$1.18 | +44.4% | 3 |
| Next fiscal year (2027) | −$0.55 | −$1.46 | −$0.01 | −$0.66 | +16.5% | 6 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
FULC revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 4 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 4 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 4 |
FULC EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
FULC EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.18 | −$0.15 | −$0.11 | −$0.11 | −$0.11 | −40.1% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.82 | −$0.76 | −$0.66 | −$0.66 | −$0.66 | −20.2% | 1 up · 1 down |
| Next fiscal year (2027) | −$0.66 | −$0.58 | −$0.49 | −$0.49 | −$0.55 | −16.8% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
FULC earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; FULC beat in 7 of 12.
What analysts expect from FULC
5 analysts cover Fulcrum Therapeutics; their consensus rating is hold (2.80 on a 1–5 scale, where 5 is a strong buy). The average price target is $3.67, 0.5% above the latest close of $3.65. Analysts expect earnings of −$0.66 per share for 2026, +44.4% from a year earlier. For 2027 the average estimate is −$0.55 per share. Fulcrum Therapeutics beat the EPS estimate in 7 of the last 12 quarters.
Related: FULC income statement, FULC key metrics, FULC chart. See the FULC stock overview for the latest quote and news.
FULC forecast FAQ
What is Fulcrum Therapeutics's price target?
The average analyst price target for Fulcrum Therapeutics is $3.67, 0.5% above the latest close of $3.65.
Is Fulcrum Therapeutics a buy, hold or sell?
Of 5 analysts covering Fulcrum Therapeutics, 0 rate it a strong buy, 0 a buy, 4 a hold, 1 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Fulcrum Therapeutics's EPS forecast?
Analysts forecast −$0.66 per share for 2026 (range −$0.81 to −$0.51); for 2027 the estimate is −$0.55.
When does Fulcrum Therapeutics report earnings?
Fulcrum Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026; the EPS estimate is $-0.10.
Does Fulcrum Therapeutics usually beat earnings estimates?
Fulcrum Therapeutics reported EPS at or above the analyst estimate in 7 of the last 12 quarters.